1Moban NB,Lawrence J,Patrick B,et al.A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents.Lancet,2004,364:583-591.
2Cutlip DE,Baim DS,Ho KK,et al.Stent thrombosis in the modern era:a pooled analysis of multicenter coronary stent clinical trials.Circulation,2001,103,1967-1972.
3Ong AT,Hoye A,Aoki J,et al.Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal,sirolimus,or paclitaxel stent implantation.J Am Coll Cardiol,2005,45:947-953.
4Iakovou I,Schmiat T,Bonizzoni E,et al.Incidence,predictors,and outcome of thrombosis after successful implantation of drug-eluting stents.JAMA,2005,293:2126-2130.
5Chieffo A,Bonizzoni E,Orlic D,et al.Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents.Circulation,2004,109:2732-2736.
6Schofer J,Schluter M,Gershlick AH,et al.Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:double blind,randomized co ntrolled trial(E-SIRIUS).Lancet,2003,362:1093-1099.
7Moreno R,Fernandez C,Hernandez R,et al.Drug-eluting stent thrombosis results from a pooled analysis including 10 randomized studies,J Am Coll Cardiol,2005,45:954-959.
8Gregorini L,Marco J,Fajadet J,et al.Ticlopidine and asprin pretreatment reduces coagulation and platelet activation during coronary dilation procedure.J Am Coll Cardiol,1997,29:13-20.
9Lau WC,Waskell LA,Watkins PB,et al.Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction.Circulation,2003,107:32-37.
10Lau WC,Neer CJ,Watkins PB,et al.Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing.J Am Coll Cardiol,2003,41:225A.
同被引文献16
1Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14786 middle-aged men and women in Finland. Circulation, 1999, 99 (9): 1165-1172.
2Grube E, Silber S, Hauptmann KE, et al. Taxus Ⅰ: six and twelve month results from a randomized double blind trial on a slow release paelitaxel eluting stent for de Novo coronary lesions. Circulation, 2003,107: 38-42.
3Mehran R, Dangas G, Abizaid A, et al. Angiographic patterns of in stent Restenosis: classification and implications for long-term outcome. Circulation, 1999,100: 1872-1878.
4Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med, 2005, 353 (7): 653-662.
5Holmes DR Jr, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol, 2007,50 (2): 109-118.
6Popma J, Leon MB. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronaryarteries. Circulation, 2004,110: 3773-3780.
7Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-Ⅳ trial. J Am Coll Cardiol, 2005,45: 1172-1179.
8Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Circulation, 2002,106: 3143-3421.
9Newman CB, Palmer G, Silbershatz H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol, 2003,92: 670-676.
10Siqueira DA,Abizaid AA,Costa Jde R,et al.Late incomplete apposition after drug-eluting stent implantation:incidence and potential for adverse clinical outcomes.Eur Heart J,2007,28:1304-1309.
